Grimsby

Aleafia Health Announces Successful Bids in Sale and Investment Solicitation Process

Retrieved on: 
Thursday, October 12, 2023

TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (“Aleafia” or the “Corporation”) announces that Red White & Bloom Brands Inc. (“RWB”) has been selected as the successful bidder pursuant to the Court-approved sale and investment solicitation process (the “SISP”) in connection with the previously announced proceedings of Aleafia and certain of its subsidiaries under the Companies’ Creditors Arrangement Act (the “CCAA”).

Key Points: 
  • TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (“Aleafia” or the “Corporation”) announces that Red White & Bloom Brands Inc. (“RWB”) has been selected as the successful bidder pursuant to the Court-approved sale and investment solicitation process (the “SISP”) in connection with the previously announced proceedings of Aleafia and certain of its subsidiaries under the Companies’ Creditors Arrangement Act (the “CCAA”).
  • The Stalking Horse Agreement was approved by the Court in the context of the SISP, in order to establish the baseline consideration for the Corporation’s business and assets.
  • In accordance with the terms of the SISP, Aleafia will be seeking Court approval of the Sale Transactions in connection with the SISP and authority to consummate the transactions provided for therein at the approval hearing which will be held on October 27, 2023.
  • If approved by the Court, closing of the RWB Transaction is expected to occur prior to November 22, 2023, and closing of the Property Sale is expected to occur prior to November 1, 2023.

Now and Next: Futurice E40 names the e-mobility leaders spearheading the UK's booming EV market

Retrieved on: 
Monday, April 24, 2023

London, April 24, 2023 /PRNewswire/ -- Digital transformation consultancy Futurice UK today unveils its annual E40 report, celebrating the most innovative EV players driving meteoric change in 2023. Now in its third year, the biggest version of the report to date – featuring a record 22 new entries – shines a light on the people and ideas positioning the UK as a focal point for EV innovation. The report also features insights from EV sector leaders including Volkswagen Financial Services' John Lewis, Connected Kerb's Chris Pateman-Jones, and Claire Miller, Independent Mobility and Energy Advisor to Octopus Energy. 

Key Points: 
  • London, April 24, 2023 /PRNewswire/ -- Digital transformation consultancy Futurice UK today unveils its annual E40 report , celebrating the most innovative EV players driving meteoric change in 2023.
  • "We're interested in the trends, designs and partnerships used to navigate these hurdles, both now and in tomorrow's world."
  • But really, it's the luxury Model Y electric SUV – now Europe's best-selling EV – that is powering Tesla's continued, and record-breaking, growth.
  • "The sheer number of new entrants in this year's E40 show this is a market that's fast-moving and all to play for.

Aleafia Health Announces Record $43.1 Million Net Revenue in 2022 15-Month Fiscal Year, Strong $8 Million Branded Cannabis Net Revenue in Q5

Retrieved on: 
Tuesday, June 28, 2022

Branded cannabis net revenue increases 151%: Aleafia Healths branded cannabis net revenue increased 151% to $36.8 million in fiscal year 2022, from $14.6 million in the prior year.

Key Points: 
  • Branded cannabis net revenue increases 151%: Aleafia Healths branded cannabis net revenue increased 151% to $36.8 million in fiscal year 2022, from $14.6 million in the prior year.
  • Total branded cannabis revenue for the period was $47.5 million.3 Branded cannabis net revenue rose 55% to $8.0 million in the three months ended March 31, 2022, compared to $5.2 million in the three months ended March 31, 2021.
  • Branded cannabis represented 85% of total net revenue in the fiscal year ending March 31, 2022, compared to only 40% in the prior fiscal year.
  • Reaffirm net revenue guidance for fiscal year 2023: Our current annual run-rate net revenue of approximately $43 million is primarily underpinned by $288 million in adult-use branded cannabis and $119 million in medical and international revenue.